FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY

被引：0

作者：

Scarfo, L. ^{[1
,2
]}

Quaresmini, G. ^{[3
,4
]}

Ambrosetti, A. ^{[5
]}

Laurenti, L. ^{[6
]}

Rossini, F. ^{[7
,8
]}

Trentin, L. ^{[9
]}

Coscia, M. ^{[10
]}

Orlandi, E. ^{[11
]}

Mannina, D. ^{[12
]}

Torreggiani, A. ^{[13
]}

Rambaldi, A. ^{[3
,4
]}

Semenzato, G. ^{[9
]}

Innocenti, I. ^{[6
]}

Brugiatelli, M. ^{[12
]}

Cuneo, A. ^{[14
]}

Foa, R. ^{[1
,2
,3
,4
]}

Molica, S. ^{[1
,2
,5
]}

Morra, E. ^{[1
,2
,6
]}

Pane, F. ^{[1
,2
,7
,8
]}

Pizzolo, G. ^{[5
]}

Ghia, P. ^{[1
,2
]}

机构：

[1] Ist Sci San Raffaele, Dept Oncohematol, Lymphoma Unit, Milan, Italy

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] Azienda Osped Papa Giovanni XXIII, Hematol Unit, Bergamo, Italy

[4] Azienda Osped Papa Giovanni XXIII, Bone Marrow Transplant Unit, Bergamo, Italy

[5] Policlin GB Rossi, Dept Hematol, Verona, Italy

[6] Univ Cattolica Sacro Cuore, Inst Hematol, I-00168 Rome, Italy

[7] Osped San Gerardo, Div Ematol, Monza, Italy

[8] Osped San Gerardo, Ctr TMO, Monza, Italy

[9] Univ Padua, Sch Med, Dept Med, Hematol & Clin Immunol Branch, Padua, Italy

[10] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy

[11] Fdn IRCCS Policlin San Matteo, Dept Oncohematol, Hematol Unit, Pavia, Italy

[12] Osped Papardo, Div Ematol, Messina, Italy

[13] Fdn IRCCS Policlin San Matteo, Pavia, Italy

[14] Azienda Osped Univ S Anna, Sect Hematol, Ferrara, Italy

来源：

HAEMATOLOGICA | 2014年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1512

引用

页码：587 / 587

页数：1

共 50 条

[31] BENDAMUSTINE AND RITUXIMAB AS FIRST OR SECOND LINE THERAPY IN ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Gozzetti, A.
Ciolli, S.
Candi, V.
Breschi, C.
Fabbri, A.
Schiattone, L.
Cencini, E.
Papini, G.
Raspadori, D.
Defina, M.
Aprile, L.
Bosi, A.
Bocchia, M.
HAEMATOLOGICA, 2014, 99 : 592 - 592
[32] CHROMOSOMAL STUDY OF PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)
FORT, S
KANTER, RJ
PHILLIPS, EA
RAI, KR
SAWITSKY, A
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 429 - 429
[33] Understanding Patient and Physician Perceptions Regarding Treatment-Related Adverse Events in First-Line Chronic Lymphocytic Leukemia (CLL)
Sile, Bersabeh
Horchi, Dahbia
Rault, Bleuenn
Mulvihill, Emily
Beusterien, Kathleen
Stewart, Katherine
De Miranda, Paulo Andre P. Palhares
Guillaume, Xavier
BLOOD, 2023, 142
[34] Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p)
Strati, Paolo
Keating, Michael J.
O'Brien, Susan Mary
Ferrajoli, Alessandra
Burger, Jan Andreas
Faderl, Stefan
Jain, Nitin
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[35] Post-remissional rituximab administration for the treatment of older chronic lymphocytic leukemia (CLL) patients responsive to first-line therapy with chlorambucil and prednisone
Mauro, F. R.
Del Giudice, I.
Gentile, M.
De Angelis, G.
De Propris, M. S.
Ghia, M. E.
Marinelli, M.
Quattrocchi, L.
Fisinger, P.
Guarini, A.
Foa, R.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 44 - 45
[36] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
Jain, Nitin
Keating, Michael J.
Thompson, Philip A.
Ferrajoli, Alessandra
Senapati, Jayastu
Burger, Jan A.
Borthakur, Gautam
Takahashi, Koichi
Estrov, Zeev E.
Konopleva, Marina
Sasaki, Koji
Kadia, Tapan M.
Pemmaraju, Naveen
Daver, Naval
Jabbour, Elias
DiNardo, Courtney D.
Alvarado, Yesid
Yilmaz, Musa
Bose, Prithviraj
Ohanian, Maro
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey L.
Wang, Sa A.
Nassar, Sameh
Garg, Naveen
Hwang, Hyunsoo
Wang, Xuemei
Cruz, Nichole
Ayala, Ana
Plunkett, William
Kantarjian, Hagop
Gandhi, Varsha
Wierda, William G.
BLOOD, 2022, 140
[37] Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data
Jain, Nitin
Keating, Michael J.
Thompson, Philip A.
Ferrajoli, Alessandra
Senapati, Jayastu
Burger, Jan A.
Borthakur, Gautam
Swaminathan, Mahesh
Takahashi, Koichi
Estrov, Zeev
Konopleva, Marina Y.
Sasaki, Koji
Kadia, Tapan M.
Pemmaraju, Naveen
Daver, Naval
Jabbour, Elias
DiNardo, Courtney D.
Valero, Yesid Alvarado
Yilmaz, Musa
Bose, Prithviraj
Ohanian, Maro
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey L.
Wang, Sa A.
Nassar, Sameh
Garg, Naveen
Hwang, Hyunsoo
Wang, Xuemei
Cruz, Nichole
Ayala, Ana
Plunkett, William
Kantarjian, Hagop M.
Gandhi, Varsha
Wierda, William G.
BLOOD, 2023, 142
[38] Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry
Kutsch, Nadine
Giza, Adam
Robrecht, Sandra
Stumpf, Janina
Federhen, Anno
Stoltefuss, Andrea
Vehling-Kaiser, Ursula
Koenigsmann, Michael
Tausch, Eugen
Schneider, Christof
Stilgenbauer, Stephan
Illmer, Thomas
Schlag, Rudolf
Doerfel, Steffen
Gaska, Tobias
Kiehl, Michael
Mueller-Hagen, Sigrun
Moorahrend, Enno
Linde, Hartmut
Schlenska-Lange, Anke
von Tresckow, Julia
Fischer, Kirsten
Eichhorst, Barbara
Hallek, Michael
Fink, Anna Maria
EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 235 - 241
[39] AN ASSESSMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE ELIGIBLE FOR FIRST-LINE THERAPY BUT UNSUITABLE FOR FULL-DOSE FLUDARABINE
Jeyakumaran, D.
Cote, S.
Kempel-Waibel, A.
HAEMATOLOGICA, 2016, 101 : 724 - 724
[40] Fludarabine, cyclophosphamide and rituximab (FCR) in front line treatment of patients with chronic lymphocytic leukemia (CLL)
Grifi, Fatiha
Bougherira, Soraya
Djenouni, Amel
LEUKEMIA & LYMPHOMA, 2017, 58 : 94 - 94

← 1 2 3 4 5 →